defens natur healthcar firm offer
page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut close total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad stelara tremfya
well cancer drug darzalex imbruvica medic devic
group bring almost one third sale compani hold
control posit mani area includ orthoped
larg round remain busi line despit
manufactur issu past sever year group still
hold mani brand strong price power
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
minim invas surgic tool robot instrument
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm drug
divis focus follow therapeut area immunolog oncolog
neurolog pulmonari cardiolog metabol diseas devic
segment focus orthoped surgeri tool vision care
smaller area last segment consum focus babi care beauti
oral care over-the-count drug women health geograph
half total revenu gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
defens natur healthcar firm offer
concern around global recess due coronaviru
disrupt weigh global market
defens natur healthcar hold rel
basi dont expect signific chang
healthcar moat rate may make downward
adjust valuat healthcar account
near-term challeng expect modest chang
rel recent stock price movement base case
call strong econom rebound follow
recess modest impact
healthcar valuat given defens natur
compani howev coronaviru pandem exert
sustain impact economi significantli higher
number patient unemploy uninsur
underinsur could reduc healthcar demand
greater extent expect govern effort reduc
near-term hit keep harder-hit industri
busi effect treatment emerg
near-term effect coronaviru expect critic
therapi crowd elect procedur new
product non-critical-car product fewer elect
procedur weigh devic maker servic
focus covid-specif case could reduc
profit health insur brand drug firm
alreadi focus specialti drug expect less impact
industri drug administ hospit could
still feel crowd coronaviru patient also
clinic develop timelin probabl face
delay due coronaviru disrupt like slow
new product launch addit coronaviru
impact credit market could weigh heavili
indebt compani hospit firm
compani recent complet major acquisit
outlook coronaviru global
economi well potenti new treatment
coronaviru pleas see
widespread diseas drug pipelin progress
increas fair valu estim per share
project higher oper margin base
expect oper improv market
administr effort product ration
profit product also like continu faster growth
drug group highest margin segment compar
segment help support strong margin
within core driver cash flow new immunolog
oncolog drug drive growth expect annual
earn per share growth averag next
five year strong growth new pipelin drug
off-set patent loss pharmaceut divis
expect slightli increas oper margin
next sever year wane cost-remedi effort
consum group increas cost-contain effort
throughout firm help off-set margin pressur due
loss patent protect sever high-margin drug
expect reduc depend asset sale
use occasion boost overal earn
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
success drug pipelin along magnitud
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
role number segment includ medic devic
over-the-counter medicin sever drug market
compani overli depend one particular oper
segment pharmaceut busi medic devic
group consum product repres
total sale respect addit within
segment one product domin sale despit carri
lower-margin divis maintain strong price
power post gross margin
past four year valid strong competit posit
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ robot
digit data help maintain leadership sever
medic devic area well support strong price
power switch cost remain high sever
devic product exampl physician switch
vendor hip knee devic could take week
month learn new product keep physician
tie compani product consum side new
product advanc combin solid brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
market pressur current market drug
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround drug devic talc powder also
weigh certainti ad potenti
 healthcar polici reform relat drug price
bear case creat addit pressur
believ johnson johnson carri one widest
moat healthcar sector support intellectu
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lower drug price reduc coverag less innov
drug forc drug firm push true innov
reduc power compani distribut network
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
pipelin strong entrench medic devic
consum good give compani relief
pressur pharmaceut group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oth major near-term patent loss
product hard manufactur
oj late-stag drug pipelin rel weak
size compani could creat long-term
hurdl growth
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard talc powder opioid drug
could cost billion dollar creat distract
manag
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector project
debt/ebitda close recent acquisit
actelion put dent compani cash balanc
annual free cash flow close billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever legal
surgic mesh product opioid drug litig
caus major settlement could damag sterl
reput longer term compani face typic
healthcar risk reduc price power
govern pharmaci benefit manag regulatori
delay nonapprov well increasingli aggress
gener competit small-molecul drug
biolog particular biosimilar risk remicad
increas sever biosimilar work gain
market share howev wide portfolio
product view compani overal uncertainti low
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
acquisit price rel estim fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
outlook chang drug price polici
initi result super tuesday democrat primari
show increas support former vice presid biden
whose nomin would reduc likelihood signific
drug price polici chang line
expect dont expect major chang fair
valu estim moat rate drug biotech
industri base result continu view
industri under-valued averag
due partli excess concern around potenti major
drug polici chang note elect result
bigger impact healthcar insur servic
relief ralli health insur servic provid
drug side movement toward moder
democrat biden like mean minor drug polici
chang reduc chanc medicar
scenario champion biden key oppon sen
berni sander would like significantli reduc
drug price negoti power one-pay
system elect support shift toward biden
believ like chang drug price polici
reform center around senat bill prescript drug
price reduct act pdpra howev still believ
propos hold less chanc pass base
mix level support parti havent
includ passag bill model howev
pass estim aggreg hit brand
drug sale medicar inflat price cap part
redesign propos bill believ drug
biotech industri could adapt headwind
minor impact cash flow partli cost cut
increas volum base lower price mandat
bill importantli bill would limit out-of-pocket
payment patient medicar would like help
appeas demand lower drug price
potenti drug polici chang key element
esg analysi drug firm pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
valuat chang healthcar
make chang fair valu estim
within healthcar coverag result novel
outbreak scientist
physician grappl find treatment vaccin
investor eager find firm
promis technolog contain spread viru
help current infect patient recov exampl
share gilead rose significantli monday investor
process news first confirm case
appear respond gilead
placebo-control trial remdesivir begin
china potenti gener treatment option
also test make chang
gilead fair valu estim time beyond gilead
name coverag -- like roch whose diagnost arm
coronaviru assay avail research use
yet approv -- could see tailwind need
mask soap commod hospit suppli like
demand howev assum signific long-
term financi impact outbreak unless
stay power sale tend revers
follow year limit impact valuat
effect addit suppli use prevent
spread virus tend commodity-lik product
limit abil firm retain excess
profit especi long term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
feb world organ confirm
case vast major case
diagnos china sever countri
report hand case jan declar
coronaviru outbreak global health emerg
public health emerg intern concern
pheic signifi sever threat outsid china
within healthcar coverag think
biggest financi benefit could come firm
develop novel drug treat vaccin
prevent timelin regulatori approv
therapi highli uncertain vaccin even
manufactur quickli within month firm includ
smaller biotech like inovio pharma
firm like johnson johnson glaxo clinic trial would
like take month year safeti would
need verifi administ vaccin
healthi individu addit outbreak could
abat time vaccin deem safe prospect
treatment seem immedi promis
preliminari sign effect drug includ
proven effect relat coronaviru sar
effect anim model sar anoth
kaletra proteas inhibitor
recommend china nation health commiss
treatment although benefit
use could minim multipl gener firm
alreadi manufactur drug intern market
donat kaletra suppli china gilead
jan new england journal medicin publish
detail account treatment first confirm
 patient whose worsen condit
appar revers given nucleotid analog
remdesivir seventh day hospit earli last
week howev remdesivir enter clinic trial
wuhan hospit whether drug
could approv time treat signific number
patient outbreak uncertain assum
even approv month drug would like see
biggest benefit potenti stockpil futur
outbreak although avail gener treatment
option malaria treatment chloroquin hiv booster
ritonavir seem inhibit viru accord scientist
wuhan institut virolog drug donat
make us cautiou assum multi-billion-dollar sale
similar roch tamiflu stockpil tamiflu
pandem stockpil sale peak chf billion
avian flu also hit chf billion swine flu
johnson johnson post steadi issu solid
line consensu expect
firm issu guidanc ahead project
expect strong guidanc support slight increas
fair valu estim still dont expect stock
look under-valued oper margin guidanc
basi point expans higher flat
project firm decis cut cost market
administr expens combin plan cut
support less profit consum good help
firm achiev guidanc like continu fast growth
drug group highest margin segment also help
margin expans strong oper margin
close help drive overal earn
growth reflect firm wide moat
total oper sale growth neg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
impact gener drug competit drug divis still
post highest segment growth trend
expect continu gener cancer drug zytiga
velcad well biosimilar pressur immunolog
drug remicad weigh overal drug sale howev
newer drug launch indic off-set gener
competit expect continu strong growth
newer drug includ cancer drug darzalex erleada
well immunolog drug tremfya
outsid drug group medic devic consum
group post fair growth respect
expect medic devic divis launch sever new
product help shore growth long term robot
digit devic launch next year move
compani competit posit
orthoped soft tissu surgeri consum side
compani plan pull back effort less profit
product weigh sale like improv
litig side johnson johnson work
sever legal battl believ opioid
litig cost firm close billion line
firm expect also expect talc powder
legal case cost firm billion addit given
firm product sensit toward litig model
close annual incom go legal charg
major factor esg perspect compani
 js legal posit aspect
esg includ price pressur pleas see recent
healthcar observ esg risk affect moat
pharma morningstar
sustainalyt esg risk methodolog
point opportun pharma/biotech jan
sustainalyt
own
collabor broaden deepen
esg analysi incorpor environment social
govern factor valuat analysi
pharma focus
materi esg issu social realm think
firm expos esg risk morningstar
conclud valuation-affect esg risk brand
drug firm center price risk larg litig
provid comprehens evalu support
mostli wide moat rate industri
overal see under-valued name roch
biomarin lowest exposur esg-rel
strategi focu sever diseas lower price
pressur includ base case alreadi factor much
potenti headwind intern benchmark
price could test medicar part
biomarin global price strategi rare-diseas drug
well seriou natur condit limit futur
price litig risk despit high price tag
medicar exposur minim
also like sanofi
valuat esg risk johnson johnson eli lilli look
least compel us base litig risk
valuat look under-valued
detail analysi price litig issu
top pharma name
coverag see januari
healthcar observ esg risk affect moat
pharma morningstar
trump propos drug reimport look limit
potenti lower drug price dec
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
trump administr move allow drug import
canada look challeng implement
limit scope dont expect major chang
fair valu estim drug biotechnolog
industri view administr move driven
polit motiv anoth elect cycl draw
near rather major structur shift influenc drug
price continu view price power drug
strong central pillar support moat rate
larg drug biotechnolog compani
import action propos
human servic juli propos rule
releas fda decemb dont view
plan major driver lower drug price think
implement chang would difficult
practic hard reconcil safeti provis
part feder track-and-trac system stop
counterfeit drug ensur enough drug-firm suppli low
price canada anoth concern drug firm could
limit distribut limit re-import also canada would
like support plan low drug price would
like face rise pressur support price
implement scope drug target potenti
re-import limit exclud drug biolog
inject drug drug subject fda risk evalu
mitig strategi rem drug group repres
core area focu new drug reach market
congress support drug re-import past
safe implement propos limit
enact expect similar limit around
recent propos given complex distribut
differ drug label countri see poor
prospect wide use drug re-import
background polici propos
enact pleas see healthcar observ drug
price reform weigh valuat moat look
secur biotech industri look under-valued within
report highlight impact enact chang
drug payment increas discount
medicar part doughnut hole sale also review
depth drug polici propos council
econom advisor budget
 follow test show sign asbesto
johnson johnson announc follow-up test talc
powder show sign asbesto help
reduc risk on-going litig compani
pertain potenti cancer link talc powder howev
dont expect chang fair valu base
test result follow test rigor review
sampl bottl fda found trace
element asbesto well sampl
lot product bottl use high-pow x-ray
electron technolog new test didnt identifi
asbesto new data reassur help
compani defend plaintiff claim
 js talc powder caus cancer potenti due
asbesto contamin new studi
also help reinforc strength compani brand power
key element firm wide moat despit favor
news continu model billion cost relat
like settlement talc plaintiff expect
litig drag sever quarter
eventu settlement like bring legal action close
pathway similar mani legal disput regard
side effect brand drug
 js decis recal singl lot talc powder
johnson johnson announc voluntari recal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
singl lot babi powder trace amount asbesto
found bottl purchas on-line
dont expect impact fair valu estim
plaintiff claim js talc powder
caus cancer potenti due asbesto contamin
latest recal give plaintiff fuel legal
case howev amount asbesto found less
test food drug
administr low sever confound
variabl rule includ sampl test
error counterfeit product believ
cautiou recal product
studi fda cosmet ingredi review expert
panel said talc safe also nation
conclud perin talc exposur doesnt increas
risk ovarian cancer key cancer sever plaintiff case
nevertheless recal increas uncertainti around
 js product govern continu factor
billion litig cost relat talc powder side
effect media headlin could damag
compani brand power dont expect litig
major impact compani moat
 js sale deriv consum product major
moat sourc driven intellectu properti
patent devic drug group addit mani
compani brand market differ
name brand damag done babi powder
unlik transfer compani brand also
expect pull stop support babi powder
brand limit brand damag firm
success track record defend brand
litig concern view manag
johnson johnson report third-quart result
slightli ahead consensu expect
dont see major impact fair valu estim
base out-performance continu view stock
fairli valu also firm wide moat look intact
shown steadi result across js key divis
fundament quarter look solid
continu face increas litig concern see
lawsuit manag factor
billion cost relat litig next five
year particular believ litig around side
effect opioid talc repres larger
settlement legal challeng neurosci drug
risperd compani pelvic mesh like lead
smaller settlement overal project legal cost
next five year similar previou five
year discount cash flow valuat
perspect market sentiment perspect actual
payout legal challeng past havent significantli
affect js stock price long term howev
case especi initi rule signific
turn quarter drug divis continu lead
overal growth devic consum group
improv despit gener competit drug group
recent launch continu off-set patent loss
especi oncolog immunolog expect
continu steadi growth drug unit next five
year expect steadi growth devic segment
potenti room upsid base new robot devic
reach market next two year
consum dont expect much acceler growth
base competit internet distribut channel
brand strength look less power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
 continu make solid stride advanc drug
portfolio expand indic current
market drug bring new drug market
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
side effect appeal reduc cost oct
expect recent billion rule johnson
johnson regard side effect neurosci drug
risperd fall significantli appeal dont expect
chang fair valu estim base rule
dont factor materi payment relat litig
risperd side effect discount cash flow
valuat model mani similar case alreadi
settl thrown prescrib label
risperd call signific side effect includ
gynecomastia male breast enlarg side effect
led recent juri rule expect recent rule
fall significantli base label drug
highlight side effect well similar case reach
much smaller settlement thrown legal
process johnson johnson face larger
litig risk around past opioid drug market
potenti side effect talc powder dont believ
overal legal challeng pose major threat
compani wide moat factor close
billion litig charg opioid talcum powder
legal case case could take sever year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
